The first patient has been dosed in the P-III trial (TROPION-Lung07) evaluating datopotamab deruxtecan (Dato-DXd) + pembrolizumab with/out Pt CT in a ratio (1:1:1) in 975 patients with advanced or metastatic NSCLC with PD-L1 expression 50% & without actionable genomic alterations at sites in North America, South America, EU, Asia & Oceania
Datopotamab deruxtecan is being jointly developed by Daiichi Sankyo & AstraZeneca. The 1EPs of the study are PFS & OS while 2EPs incl. ORR, DoR, time to response, DCR, PFS, PFS2 & safety
Datopotamab deruxtecan is a TROP2-directed ADC & is being developed by using DXd ADC technology. Early trials, incl. (TROPION-Lung02) demonstrated increased activity & manageable safety profile for the combination therapy with/out CT
Ref: Businesswire | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo Presents P-I Trial (TROPION-PanTumor01) Results of Datopotamab Deruxtecan (Dato-DXd) for Metastatic Breast Cancer at SABCS 2022
